{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,16]],"date-time":"2026-04-16T19:35:30Z","timestamp":1776368130893,"version":"3.51.2"},"reference-count":140,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2020,9,11]],"date-time":"2020-09-11T00:00:00Z","timestamp":1599782400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["PTDC\/SAU-PUB\/28736\/2017 (reference POCI-01-0145-FEDER-028736), UIDB\/04423\/2020, UIDP\/04423\/2020"],"award-info":[{"award-number":["PTDC\/SAU-PUB\/28736\/2017 (reference POCI-01-0145-FEDER-028736), UIDB\/04423\/2020, UIDP\/04423\/2020"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceuticals"],"abstract":"<jats:p>Alzheimer\u2019s disease (AD) is a multifactorial disease characterized by the presence of amyloid plaques, neurofibrillary tangles, and nerve cell death that affects, mainly, older people. After decades of investigation, the search for an efficacious treatment for AD remains and several strategies can be and are being employed in this journey. In this review, four of the most promising strategies, alongside with its most promising agents under investigation or development are highlighted. Marine natural products (MNP) are a source of unique chemical structures with useful biological activities for AD treatment. One of the most promising compounds, a marine-derived acidic oligosaccharide (GV-971) just passed phase III clinical trials with a unique mechanism of action. Combination therapy and multitargeted-directed ligand therapy (MTDL) are also two important strategies, with several examples in clinical trials, based on the belief that the best approach for AD is a therapy capable of modulating multiple target pathways. Drug repurposing, a strategy that requires a smaller investment and is less time consuming, is emerging as a strong contender with a variety of pharmacological agents resurfacing in an attempt to identify a therapeutic candidate capable of modifying the course of this disease.<\/jats:p>","DOI":"10.3390\/ph13090242","type":"journal-article","created":{"date-parts":[[2020,9,13]],"date-time":"2020-09-13T21:11:32Z","timestamp":1600031492000},"page":"242","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":47,"title":["Marine Natural Products, Multitarget Therapy and Repurposed Agents in Alzheimer\u2019s Disease"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3958-6849","authenticated-orcid":false,"given":"M\u00e1rcia","family":"Martins","sequence":"first","affiliation":[{"name":"CIIMAR\u2014Centro Interdisciplinar de Investiga\u00e7\u00e3o Marinha e Ambiental, Terminal de Cruzeiros do Porto de Leix\u00f5es, 4450-208 Matosinhos, Portugal"},{"name":"Laborat\u00f3rio de Qu\u00edmica Org\u00e2nica e Farmac\u00eautica, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9962-7548","authenticated-orcid":false,"given":"Renata","family":"Silva","sequence":"additional","affiliation":[{"name":"UCIBIO-REQUIMTE, Laborat\u00f3rio de Toxicologia, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4676-1409","authenticated-orcid":false,"given":"Madalena","family":"M. M. Pinto","sequence":"additional","affiliation":[{"name":"CIIMAR\u2014Centro Interdisciplinar de Investiga\u00e7\u00e3o Marinha e Ambiental, Terminal de Cruzeiros do Porto de Leix\u00f5es, 4450-208 Matosinhos, Portugal"},{"name":"Laborat\u00f3rio de Qu\u00edmica Org\u00e2nica e Farmac\u00eautica, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5397-4672","authenticated-orcid":false,"given":"Em\u00edlia","family":"Sousa","sequence":"additional","affiliation":[{"name":"CIIMAR\u2014Centro Interdisciplinar de Investiga\u00e7\u00e3o Marinha e Ambiental, Terminal de Cruzeiros do Porto de Leix\u00f5es, 4450-208 Matosinhos, Portugal"},{"name":"Laborat\u00f3rio de Qu\u00edmica Org\u00e2nica e Farmac\u00eautica, Faculdade de Farm\u00e1cia, Universidade do Porto, Rua de Jorge Viterbo Ferreira 228, 4050-313 Porto, Portugal"}]}],"member":"1968","published-online":{"date-parts":[[2020,9,11]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1111\/ene.13439","article-title":"Alzheimer\u2019s disease","volume":"25","author":"Lane","year":"2018","journal-title":"Eur. J. Neurol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.pharep.2014.09.004","article-title":"A review on Alzheimer\u2019s disease pathophysiology and its management: An update","volume":"67","author":"Kumar","year":"2015","journal-title":"Pharm. Rep."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Alzheimer\u2019s Association (2019). 2019 Alzheimer\u2019s disease facts and figures. Alzheimer Dement., 15, 321\u2013387.","DOI":"10.1016\/j.jalz.2019.01.010"},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"779","DOI":"10.3233\/JAD-180766","article-title":"Treatment Combinations for Alzheimer\u2019s Disease: Current and Future Pharmacotherapy Options","volume":"67","author":"Cummings","year":"2019","journal-title":"J. Alzheimer Dis. Jad."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.ijge.2016.07.003","article-title":"New Therapeutic Targets in Alzheimer\u2019s Disease","volume":"11","author":"Coman","year":"2017","journal-title":"Int. J. Gerontol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bmcl.2018.11.034","article-title":"New approaches for the treatment of Alzheimer\u2019s disease","volume":"29","author":"Fish","year":"2019","journal-title":"Bioorgan. Med. Chem. Lett."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"1408","DOI":"10.2174\/1568026617666170103163054","article-title":"Alzheimer\u2019s Disease and Natural Products: Future Regimens Emerging From Nature","volume":"17","author":"Islam","year":"2017","journal-title":"Curr. Top. Med. Chem."},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Honarpisheh, P., Reynolds, C.R., Blasco Conesa, M.P., Moruno Manchon, J.F., Putluri, N., Bhattacharjee, M.B., Urayama, A., McCullough, L.D., and Ganesh, B.P. (2020). Dysregulated Gut Homeostasis Observed Prior to the Accumulation of the Brain Amyloid-\u03b2 in Tg2576 Mice. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21051711"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1008","DOI":"10.3389\/fmicb.2020.01008","article-title":"Impact of Acute and Chronic Amyloid-\u03b2 Peptide Exposure on Gut Microbial Commensals in the Mouse","volume":"11","author":"Todorov","year":"2020","journal-title":"Front. Microbiol."},{"key":"ref_10","doi-asserted-by":"crossref","unstructured":"Andrade, S., Ramalho, M.J., Loureiro, J.A., and Pereira, M.d.C. (2019). Natural Compounds for Alzheimer\u2019s Disease Therapy: A Systematic Review of Preclinical and Clinical Studies. Int. J. Mol. Sci., 20.","DOI":"10.3390\/ijms20092313"},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/alzrt269","article-title":"Alzheimer\u2019s disease drug-development pipeline: Few candidates, frequent failures","volume":"6","author":"Cummings","year":"2014","journal-title":"Alzheimers Res."},{"key":"ref_12","doi-asserted-by":"crossref","unstructured":"Maia, M.A., and Sousa, E. (2019). BACE-1 and gamma-Secretase as Therapeutic Targets for Alzheimer\u2019s Disease. Pharmaceuticals, 12.","DOI":"10.3390\/ph12010041"},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Brahmachari, G. (2018). Chapter 3\u2014Natural Compounds and Their Derivatives as Multifunctional Agents for the Treatment of Alzheimer Disease. Discovery and Development of Neuroprotective Agents from Natural Products, Elsevier.","DOI":"10.1016\/B978-0-12-809593-5.00001-X"},{"key":"ref_14","first-page":"439","article-title":"Combotherapy and current concepts as well as future strategies for the treatment of Alzheimer\u2019s disease","volume":"10","author":"Fan","year":"2014","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Birks, J. (2006). Cholinesterase inhibitors for Alzheimer\u2019s disease. Cochrane Database Syst. Rev., Cd005593.","DOI":"10.1002\/14651858.CD005593"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1111\/j.1527-3458.2003.tb00254.x","article-title":"The neuropharmacological basis for the use of memantine in the treatment of Alzheimer\u2019s disease","volume":"9","author":"Rogawski","year":"2003","journal-title":"CNS Drug Rev."},{"key":"ref_17","first-page":"15","article-title":"Efficacy and Tolerability of a Combination Treatment of Memantine and Donepezil for Alzheimer\u2019s Disease: A Literature Review Evidence","volume":"3","author":"Riverol","year":"2011","journal-title":"Eur. Neurol. J."},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Chen, R., Chan, P.-T., Chu, H., Lin, Y.-C., Chang, P.-C., Chen, C.-Y., and Chou, K.-R. (2017). Treatment effects between monotherapy of donepezil versus combination with memantine for Alzheimer disease: A meta-analysis. PLoS ONE, 12.","DOI":"10.1371\/journal.pone.0183586"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"1299833","DOI":"10.1080\/20016689.2017.1299833","article-title":"Filling the gap in CNS drug development: Evaluation of the role of drug repurposing","volume":"5","author":"Caban","year":"2017","journal-title":"J. Mark. Access Health Policy"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.3233\/JAD-190744","article-title":"Current and Emerging Pharmacological Targets for the Treatment of Alzheimer\u2019s Disease","volume":"72","author":"Morsy","year":"2019","journal-title":"J. Alzheimer\u2019s Dis."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Ghosh, A., C\u00e1rdenas, E., and Osswald, H. (2016). The Design, Development, and Evaluation of BACE1 Inhibitors for the Treatment of Alzheimer\u2019s Disease. Alzheimer\u2019s Disease II, Springer.","DOI":"10.1007\/7355_2016_16"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"1611","DOI":"10.4155\/fmc-2017-0086","article-title":"Dual\/multitargeted xanthone derivatives for Alzheimer\u2019s disease: Where do we stand?","volume":"9","author":"Cruz","year":"2017","journal-title":"Future Med. Chem."},{"key":"ref_23","first-page":"272","article-title":"Alzheimer\u2019s disease drug development pipeline: 2019","volume":"5","author":"Cummings","year":"2019","journal-title":"Alzheimers Dement."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1186\/s13195-016-0207-9","article-title":"Drug development in Alzheimer\u2019s disease: The path to 2025","volume":"8","author":"Cummings","year":"2016","journal-title":"Alzheimer Res. Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"1681","DOI":"10.4155\/fmc.12.109","article-title":"An alternative approach to drug discovery for Alzheimer\u2019s disease dementia","volume":"4","author":"Schubert","year":"2012","journal-title":"Future Med. Chem."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1002\/ddr.21587","article-title":"Natural products and their derivatives as multifunctional ligands against Alzheimer\u2019s disease","volume":"81","author":"Patil","year":"2020","journal-title":"Drug Dev. Res."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.cbpa.2008.03.016","article-title":"The impact of natural products upon modern drug discovery","volume":"12","author":"Ganesan","year":"2008","journal-title":"Curr. Opin. Chem. Biol."},{"key":"ref_28","first-page":"1377","article-title":"Marine compounds for the therapeutic treatment of neurological disorders","volume":"15","author":"Alonso","year":"2005","journal-title":"Patents"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/md14010005","article-title":"New Drugs from Marine Organisms in Alzheimer\u2019s Disease","volume":"14","author":"Russo","year":"2015","journal-title":"Mar. Drugs"},{"key":"ref_30","doi-asserted-by":"crossref","unstructured":"Rubiolo, J., Alonso, E., and Cagide, E. (2014). Marine Compounds as a Starting Point to Drugs. Seafood and Freshwater Toxins, Routledge.","DOI":"10.1201\/b16662-48"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1039\/C7NP00052A","article-title":"Marine natural products","volume":"35","author":"Blunt","year":"2018","journal-title":"Nat. Prod. Rep."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s12272-014-0503-5","article-title":"Natural products from marine organisms with neuroprotective activity in the experimental models of Alzheimer\u2019s disease, Parkinson\u2019s disease and ischemic brain stroke: Their molecular targets and action mechanisms","volume":"38","author":"Choi","year":"2015","journal-title":"Arch. Pharmacal Res."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1016\/j.neurobiolaging.2006.02.015","article-title":"Targeting soluble Abeta peptide with Tramiprosate for the treatment of brain amyloidosis","volume":"28","author":"Gervais","year":"2007","journal-title":"Neurobiol. Aging"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"473","DOI":"10.2174\/156720507781788882","article-title":"Alzhemed: A potential treatment for Alzheimer\u2019s disease","volume":"4","author":"Aisen","year":"2007","journal-title":"Curr. Alzheimer Res."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1007\/BF03654836","article-title":"The potential protective effect of tramiprosate (homotaurine) against Alzheimer\u2019s disease: A review","volume":"24","author":"Caltagirone","year":"2012","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"102","DOI":"10.5114\/aoms.2011.20612","article-title":"Tramiprosate in mild-to-moderate Alzheimer\u2019s disease\u2014A randomized, double-blind, placebo-controlled, multi-centre study (the Alphase Study)","volume":"7","author":"Aisen","year":"2011","journal-title":"Arch. Med. Sci."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"56","DOI":"10.1124\/mol.65.1.56","article-title":"Hydroxy metabolites of the Alzheimer\u2019s drug candidate 3-[(2, 4-dimethoxy) benzylidene]-anabaseine dihydrochloride (GTS-21): Their molecular properties, interactions with brain nicotinic receptors, and brain penetration","volume":"65","author":"Kem","year":"2004","journal-title":"Mol. Pharmacol."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"255","DOI":"10.3390\/md403255","article-title":"The Nemertine Toxin Anabaseine and Its Derivative DMXBA (GTS-21): Chemical and Pharmacological Properties","volume":"4","author":"Kem","year":"2006","journal-title":"Mar. Drugs"},{"key":"ref_39","doi-asserted-by":"crossref","unstructured":"Dev, K., and Maurya, R. (2017). Marine-Derived Anti-Alzheimer\u2019s Agents of Promise: Clinical Aspects and Mode of Action. Neuroprotect. Nat. Prod. Clin. Aspects Mode Action, 153\u2013184.","DOI":"10.1002\/9783527803781.ch7"},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.neurobiolaging.2017.10.021","article-title":"Alpha7 nicotinic acetylcholine receptor-specific agonist DMXBA (GTS-21) attenuates A\u03b2 accumulation through suppression of neuronal \u03b3-secretase activity and promotion of microglial amyloid-\u03b2 phagocytosis and ameliorates cognitive impairment in a mouse model of Alzheimer\u2019s disease","volume":"62","author":"Takata","year":"2018","journal-title":"Neurobiol. Aging"},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"1903","DOI":"10.1001\/jama.2010.1510","article-title":"Docosahexaenoic acid supplementation and cognitive decline in Alzheimer disease: A randomized trial","volume":"304","author":"Quinn","year":"2010","journal-title":"JAMA"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"148","DOI":"10.4103\/ijabmr.IJABMR_367_17","article-title":"Pharmacokinetics and Oxidation Parameters in Volunteers Supplemented with Microencapsulated Docosahexaenoic Acid","volume":"8","author":"Petyaev","year":"2018","journal-title":"Int. J. Appl. Basic Med. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"172801","DOI":"10.1155\/2015\/172801","article-title":"Omega-3 Fatty Acids in Early Prevention of Inflammatory Neurodegenerative Disease: A Focus on Alzheimer\u2019s Disease","volume":"2015","author":"Thomas","year":"2015","journal-title":"BioMed Res. Int."},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1016\/j.neuron.2004.08.013","article-title":"Docosahexaenoic acid protects from dendritic pathology in an Alzheimer\u2019s disease mouse model","volume":"43","author":"Calon","year":"2004","journal-title":"Neuron"},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"3032","DOI":"10.1523\/JNEUROSCI.4225-04.2005","article-title":"A diet enriched with the omega-3 fatty acid docosahexaenoic acid reduces amyloid burden in an aged Alzheimer mouse model","volume":"25","author":"Lim","year":"2005","journal-title":"J. Neurosci."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1172\/JCI25420","article-title":"A role for docosahexaenoic acid-derived neuroprotectin D1 in neural cell survival and Alzheimer disease","volume":"115","author":"Lukiw","year":"2005","journal-title":"J. Clin. Investig."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1001\/archneur.63.10.1402","article-title":"Omega-3 fatty acid treatment in 174 patients with mild to moderate Alzheimer disease: OmegAD study: A randomized double-blind trial","volume":"63","author":"Cederholm","year":"2006","journal-title":"Arch. Neurol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"4385","DOI":"10.1523\/JNEUROSCI.0055-07.2007","article-title":"Dietary docosahexaenoic acid and docosapentaenoic acid ameliorate amyloid-beta and tau pathology via a mechanism involving presenilin 1 levels","volume":"27","author":"Green","year":"2007","journal-title":"J. Neurosci."},{"key":"ref_49","first-page":"140","article-title":"Fish consumption, long-chain omega-3 fatty acids and risk of cognitive decline or Alzheimer disease: A complex association","volume":"5","author":"Fotuhi","year":"2009","journal-title":"Nat. Clin. Pract. Neurol."},{"key":"ref_50","doi-asserted-by":"crossref","unstructured":"Zhao, Y., Calon, F., Julien, C., Winkler, J.W., Petasis, N.A., Lukiw, W.J., and Bazan, N.G. (2011). Docosahexaenoic acid-derived neuroprotectin D1 induces neuronal survival via secretase- and PPARgamma-mediated mechanisms in Alzheimer\u2019s disease models. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0015816"},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"14028","DOI":"10.1074\/jbc.M110.182329","article-title":"Docosahexaenoic acid reduces amyloid beta production via multiple pleiotropic mechanisms","volume":"286","author":"Grimm","year":"2011","journal-title":"J. Biol. Chem."},{"key":"ref_52","doi-asserted-by":"crossref","first-page":"521","DOI":"10.3233\/JAD-170161","article-title":"Bryostatin Effects on Cognitive Function and PKC\u025b in Alzheimer\u2019s Disease Phase IIa and Expanded Access Trials","volume":"58","author":"Nelson","year":"2017","journal-title":"J. Alzheimer\u2019s Dis. Jad."},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"555","DOI":"10.3233\/JAD-180759","article-title":"A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Assessing Safety, Tolerability, and Efficacy of Bryostatin in the Treatment of Moderately Severe to Severe Alzheimer\u2019s Disease","volume":"67","author":"Farlow","year":"2019","journal-title":"J. Alzheimer\u2019s Dis. Jad."},{"key":"ref_54","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/j.1527-3458.2006.00001.x","article-title":"Bryostatin-1: Pharmacology and Therapeutic Potential as a CNS Drug","volume":"12","author":"Sun","year":"2006","journal-title":"CNS Drug Rev."},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.3233\/JAD-141221","article-title":"PKCepsilon deficits in Alzheimer\u2019s disease brains and skin fibroblasts","volume":"43","author":"Khan","year":"2015","journal-title":"J. Alzheimer\u2019s Dis.Jad."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"1497","DOI":"10.4155\/fmc-2018-0012","article-title":"Review of bioactive secondary metabolites from marine bryozoans in the progress of new drugs discovery","volume":"10","author":"Tian","year":"2018","journal-title":"Future Med. Chem."},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"1166","DOI":"10.1002\/chem.201903128","article-title":"Unlocking the Drug Potential of the Bryostatin Family: Recent Advances in Product Synthesis and Biomedical Applications","volume":"26","author":"Wu","year":"2020","journal-title":"Chem. Eur. J."},{"key":"ref_58","doi-asserted-by":"crossref","unstructured":"Bharate, S., Manda, S., Joshi, P., Singh, B., and Vishwakarma, R. (2012). Total synthesis and anti-cholinesterase activity of marine-derived bis-indole alkaloid fascaplysin. Rapid Commun. Res. Med. Chem., 3.","DOI":"10.1039\/c2md20076g"},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.ejmech.2015.10.049","article-title":"Discovery of a marine-derived bis-indole alkaloid fascaplysin, as a new class of potent P-glycoprotein inducer and establishment of its structure\u2013activity relationship","volume":"107","author":"Manda","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"4741","DOI":"10.1021\/acschemneuro.9b00503","article-title":"Fascaplysin Derivatives Are Potent Multitarget Agents against Alzheimer\u2019s Disease: In Vitro and in Vivo Evidence","volume":"10","author":"Pan","year":"2019","journal-title":"ACS Chem. Neurosci."},{"key":"ref_61","doi-asserted-by":"crossref","unstructured":"Sun, Q., Liu, F., Sang, J., Lin, M., Ma, J., Xiao, X., Yan, S., Naman, C.B., Wang, N., and He, S. (2019). 9-Methylfascaplysin Is a More Potent A\u03b2 Aggregation Inhibitor than the Marine-Derived Alkaloid, Fascaplysin, and Produces Nanomolar Neuroprotective Effects in SH-SY5Y Cells. Mar. Drugs, 17.","DOI":"10.3390\/md17020121"},{"key":"ref_62","unstructured":"(2020, April 09). Alzforum. China Approves Seaweed Sugar as First New Alzheimer\u2019s Drug in 17 Years. Available online: https:\/\/www.alzforum.org\/news\/research-news\/china-approves-seaweed-sugar-first-new-alzheimers-drug-17-years."},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"96","DOI":"10.1179\/174313206X152483","article-title":"A marine-derived acidic oligosaccharide sugar chain specifically inhibits neuronal cell injury mediated by beta-amyloid-induced astrocyte activation in vitro","volume":"29","author":"Wang","year":"2007","journal-title":"Neurol Res."},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"787","DOI":"10.1038\/s41422-019-0216-x","article-title":"Sodium oligomannate therapeutically remodels gut microbiota and suppresses gut bacterial amino acids-shaped neuroinflammation to inhibit Alzheimer\u2019s disease progression","volume":"29","author":"Wang","year":"2019","journal-title":"Cell Res."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1007\/s40265-020-01268-1","article-title":"Sodium Oligomannate: First Approval","volume":"80","author":"Syed","year":"2020","journal-title":"Drugs"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"315","DOI":"10.1007\/s40262-017-0608-3","article-title":"Clinical Pharmacokinetics and Safety of ALZ-801, a Novel Prodrug of Tramiprosate in Development for the Treatment of Alzheimer\u2019s Disease","volume":"57","author":"Hey","year":"2018","journal-title":"Clin. Pharm."},{"key":"ref_67","unstructured":"(2020, April 18). Alzheon. ALZ-801\u2014Phase 3-Ready Oral Small Molecule Program Designed to Inhibit Formation of Neurotoxic Soluble Amyloid Oligomers Represents Optimized and Differentiated Treatment Paradigm for Alzheimer\u2019s Disease. Available online: https:\/\/alzheon.com\/alz-801-program-white-paper\/."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1111\/j.1447-0594.2011.00827.x","article-title":"3-(2,4-dimethoxybenzylidene)-anabaseine: A promising candidate drug for Alzheimer\u2019s disease?","volume":"12","author":"Zawieja","year":"2012","journal-title":"Geriatr. Gerontol. Int."},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"2433","DOI":"10.1016\/j.ejmech.2010.02.027","article-title":"A computational study of the binding of 3-(arylidene) anabaseines to two major brain nicotinic acetylcholine receptors and to the acetylcholine binding protein","volume":"45","author":"Slavov","year":"2010","journal-title":"Eur. J. Med. Chem."},{"key":"ref_70","first-page":"172","article-title":"The role of nicotinic acetylcholine receptors in Alzheimer\u2019s disease","volume":"99","author":"Oddo","year":"2006","journal-title":"J. Physiol."},{"key":"ref_71","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1016\/j.bmcl.2011.11.090","article-title":"Discovery of novel \u03b17 nicotinic acetylcholine receptor ligands via pharmacophoric and docking studies of benzylidene anabaseine analogs","volume":"22","author":"Kombo","year":"2012","journal-title":"Bioorg. Med. Chem. Lett."},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1016\/0041-0101(71)90039-0","article-title":"Isolation and structure of a hoplonemertine toxin","volume":"9","author":"Kem","year":"1971","journal-title":"Toxicon"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"3040","DOI":"10.1038\/emboj.2009.227","article-title":"Structural determinants for interaction of partial agonists with acetylcholine binding protein and neuronal alpha7 nicotinic acetylcholine receptor","volume":"28","author":"Hibbs","year":"2009","journal-title":"EMBO J."},{"key":"ref_74","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1002\/ddr.430310208","article-title":"Cytoprotective actions of 2,4-dimethoxybenzylidene anabaseine in differentiated PC12 cells and septal cholinergic neurons","volume":"31","author":"Martin","year":"1994","journal-title":"Drug Dev. Res."},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1194\/jlr.D800056-JLR200","article-title":"Whole-body synthesis-secretion rates of long-chain n-3 PUFAs from circulating unesterified alpha-linolenic acid in unanesthetized rats","volume":"50","author":"Gao","year":"2009","journal-title":"J. Lipid Res."},{"key":"ref_76","doi-asserted-by":"crossref","unstructured":"Watters, C., Edmonds, C., Rosner, L., Sloss, K., and Leung, P. (2012). A cost analysis of EPA and DHA in fish, supplements and foods. J. Nutr. Food Sci., 2.","DOI":"10.4172\/2155-9600.1000159"},{"key":"ref_77","unstructured":"Brady, S.T., Siegel, G.J., Albers, R.W., and Price, D.L. (2012). Chapter 36\u2014Lipid Mediators: Eicosanoids, Docosanoids and Platelet-Activating Factor. Basic Neurochemistry, Academic Press. [8th ed.]."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"6846","DOI":"10.1021\/ja00388a092","article-title":"Isolation and structure of bryostatin 1","volume":"104","author":"Pettit","year":"1982","journal-title":"J. Am. Chem. Soc."},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1039\/b009211h","article-title":"The chemistry and biology of the bryostatin antitumour macrolides","volume":"19","author":"Hale","year":"2002","journal-title":"Nat. Prod. Rep."},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.flm.2018.06.001","article-title":"A marine sponge Fascaplysinopsis sp. derived alkaloid fascaplysin inhibits the HepG2 hepatocellular carcinoma cell","volume":"2","author":"Rajivgandhi","year":"2018","journal-title":"Front. Lab. Med."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Gil-Martins, E., Barbosa, D.J., Silva, V., Remi\u00e3o, F., and Silva, R. (2020). Dysfunction of ABC transporters at the blood-brain barrier: Role in neurological disorders. Pharmacol. Ther., 107554.","DOI":"10.1016\/j.pharmthera.2020.107554"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1021\/jm7009364","article-title":"Multi-target-directed ligands to combat neurodegenerative diseases","volume":"51","author":"Cavalli","year":"2008","journal-title":"J. Med. Chem."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"8881","DOI":"10.1021\/acs.jmedchem.9b00017","article-title":"Rational Design of Multitarget-Directed Ligands: Strategies and Emerging Paradigms","volume":"62","author":"Zhou","year":"2019","journal-title":"J. Med. Chem."},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"853","DOI":"10.1039\/C4MD00069B","article-title":"Two diseases, one approach: Multitarget drug discovery in Alzheimer\u2019s and neglected tropical diseases","volume":"5","author":"Prati","year":"2014","journal-title":"MedChemComm"},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1080\/14728214.2016.1241232","article-title":"Emerging drugs to reduce abnormal \u03b2-amyloid protein in Alzheimer\u2019s disease patients","volume":"21","author":"Panza","year":"2016","journal-title":"Expert Opin. Emerg. Drugs"},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"1966","DOI":"10.1074\/jbc.M114.586602","article-title":"A Food and Drug Administration-approved asthma therapeutic agent impacts amyloid \u03b2 in the brain in a transgenic model of Alzheimer disease","volume":"290","author":"Hori","year":"2015","journal-title":"J. Biol. Chem."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1007\/s40261-017-0549-5","article-title":"Pharmacokinetics of Cromolyn and Ibuprofen in Healthy Elderly Volunteers","volume":"37","author":"Brazier","year":"2017","journal-title":"Clin. Drug Investig."},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1007\/BF03325217","article-title":"A randomized controlled study on effects of ibuprofen on cognitive progression of Alzheimer\u2019s disease","volume":"21","author":"Pasqualetti","year":"2009","journal-title":"Aging Clin. Exp. Res."},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1038\/35102591","article-title":"A subset of NSAIDs lower amyloidogenic Abeta42 independently of cyclooxygenase activity","volume":"414","author":"Weggen","year":"2001","journal-title":"Nature"},{"key":"ref_90","doi-asserted-by":"crossref","unstructured":"Zhang, C., Griciuc, A., Hudry, E., Wan, Y., Quinti, L., Ward, J., Forte, A., Shen, X., Ran, C., and Elmaleh, D. (2018). Cromolyn Reduces Levels of the Alzheimer\u2019s Disease-Associated Amyloid \u03b2-Protein by Promoting Microglial Phagocytosis. Sci. Rep., 8.","DOI":"10.1038\/s41598-018-19641-2"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1080\/13543784.2017.1267726","article-title":"AVP-786 for the treatment of agitation in dementia of the Alzheimer\u2019s type","volume":"26","author":"Garay","year":"2017","journal-title":"Expert Opin. Investig. Drugs"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1016\/j.drudis.2018.11.007","article-title":"A new generation of antidepressants: An update on the pharmaceutical pipeline for novel and rapid-acting therapeutics in mood disorders based on glutamate\/GABA neurotransmitter systems","volume":"24","author":"Wilkinson","year":"2019","journal-title":"Drug Discov. Today"},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"S458","DOI":"10.1016\/j.euroneuro.2018.11.686","article-title":"AXS-05 (Dextromethorphan\/Bupropion): Psychopharmacology and the potential for therapeutic application in the treatment of neuropsychiatric symptoms","volume":"29","author":"Jones","year":"2019","journal-title":"Eur. Neuropsychopharmacol."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s40266-019-00668-7","article-title":"Current Agents in Development for Treating Behavioral and Psychological Symptoms Associated with Dementia","volume":"36","author":"Ahmed","year":"2019","journal-title":"Drugs Aging"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1017\/S1092852919001470","article-title":"Dextromethorphan\/Bupropion: A Novel Oral NMDA (N-methyl-d-aspartate) Receptor Antagonist with Multimodal Activity","volume":"24","author":"Stahl","year":"2019","journal-title":"CNS Spectr."},{"key":"ref_96","doi-asserted-by":"crossref","first-page":"682","DOI":"10.1001\/jama.2014.93","article-title":"Effect of Citalopram on Agitation in Alzheimer Disease: The CitAD Randomized Clinical Trial","volume":"311","author":"Porsteinsson","year":"2014","journal-title":"JAMA"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.pharmthera.2016.01.016","article-title":"Dextromethorphan: An update on its utility for neurological and neuropsychiatric disorders","volume":"159","author":"Nguyen","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"170","DOI":"10.1016\/j.pharmthera.2016.04.010","article-title":"Pharmacology of dextromethorphan: Relevance to dextromethorphan\/quinidine (Nuedexta\u00ae) clinical use","volume":"164","author":"Taylor","year":"2016","journal-title":"Pharmacol. Ther."},{"key":"ref_99","first-page":"295","article-title":"The influence of CYP2D6 polymorphism and quinidine on the disposition and antitussive effect of dextromethorphan in humans","volume":"60","author":"Capon","year":"1996","journal-title":"Clin. Pharm."},{"key":"ref_100","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1177\/2045125316629071","article-title":"Bupropion: A systematic review and meta-analysis of effectiveness as an antidepressant","volume":"6","author":"Patel","year":"2016","journal-title":"Adv. Psychopharmacol."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2017\/8587260","article-title":"Xanthone and Flavone Derivatives as Dual Agents with Acetylcholinesterase Inhibition and Antioxidant Activity as Potential Anti-Alzheimer Agents","volume":"2017","author":"Cruz","year":"2017","journal-title":"J. Chem."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"3689","DOI":"10.1002\/anie.200700256","article-title":"A small molecule targeting the multifactorial nature of Alzheimer\u2019s disease","volume":"46","author":"Cavalli","year":"2007","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_103","first-page":"152","article-title":"Memoquin: A multi-target-directed ligand as an innovative therapeutic opportunity for Alzheimer\u2019s disease","volume":"6","author":"Bolognesi","year":"2009","journal-title":"Neurother. J. Am. Soc. Exp. Neurother."},{"key":"ref_104","doi-asserted-by":"crossref","unstructured":"Ortiz, C.J.C., de Freitas Silva, M., Gontijo, V.S., Viegas, F.P.D., Dias, K.S.T., and Viegas, C. (2019). Design of multi-target directed ligands as a modern approach for the development of innovative drug candidates for Alzheimer\u2019s disease. Methods in Pharmacology and Toxicology, Humana Press Inc.","DOI":"10.1007\/7653_2018_2"},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"7883","DOI":"10.1021\/jm901123n","article-title":"Toward a Rational Design of Multitarget-Directed Antioxidants: Merging Memoquin and Lipoic Acid Molecular Frameworks","volume":"52","author":"Bolognesi","year":"2009","journal-title":"J. Med. Chem."},{"key":"ref_106","doi-asserted-by":"crossref","unstructured":"Capurro, V., Busquet, P., Lopes, J.P., Bertorelli, R., Tarozzo, G., Bolognesi, M.L., Piomelli, D., Reggiani, A., and Cavalli, A. (2013). Pharmacological characterization of memoquin, a multi-target compound for the treatment of Alzheimer\u2019s disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0056870"},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/anie.201410456","article-title":"Multitarget drug discovery for Alzheimer\u2019s disease: Triazinones as BACE-1 and GSK-3\u03b2 inhibitors","volume":"54","author":"Prati","year":"2015","journal-title":"Angew. Chem. Int. Ed. Engl."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"466","DOI":"10.3390\/molecules21040466","article-title":"Navigating the Chemical Space of Multitarget-Directed Ligands: From Hybrids to Fragments in Alzheimer\u2019s Disease","volume":"21","author":"Prati","year":"2016","journal-title":"Molecules"},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"1665","DOI":"10.1021\/acschemneuro.5b00121","article-title":"3,4-Dihydro-1,3,5-triazin-2(1H)-ones as the First Dual BACE-1\/GSK-3\u03b2 Fragment Hits against Alzheimer\u2019s Disease","volume":"6","author":"Prati","year":"2015","journal-title":"Acs Chem. Neurosci."},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1080\/08927022.2019.1691203","article-title":"Insights into the molecular basis of acetylcholinesterase inhibition by xanthones: An integrative in silico and in vitro approach","volume":"46","author":"Alawi","year":"2020","journal-title":"Mol. Simul."},{"key":"ref_111","doi-asserted-by":"crossref","unstructured":"Kou, X., Song, L., Wang, Y., Yu, Q., Ju, H., Yang, A., and Shen, R. (2020). Design, synthesis and anti-Alzheimer\u2019s disease activity study of xanthone derivatives based on multi-target strategy. Bioorg. Med. Chem. Lett., 30.","DOI":"10.1016\/j.bmcl.2019.126927"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"e47","DOI":"10.1017\/jns.2016.41","article-title":"Flavonoids: An overview","volume":"5","author":"Panche","year":"2016","journal-title":"J. Nutr. Sci."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ejmech.2018.05.004","article-title":"A review on flavonoid-based scaffolds as multi-target-directed ligands (MTDLs) for Alzheimer\u2019s disease","volume":"152","author":"Babaei","year":"2018","journal-title":"Eur. J. Med. Chem."},{"key":"ref_114","doi-asserted-by":"crossref","unstructured":"Duraes, F., Pinto, M., and Sousa, E. (2018). Old Drugs as New Treatments for Neurodegenerative Diseases. Pharmaceuticals, 11.","DOI":"10.3390\/ph11020044"},{"key":"ref_115","first-page":"385","article-title":"Chapter 23\u2014The Future of Drug Repositioning: Old Drugs, New Opportunities","volume":"Volume 46","author":"Macor","year":"2011","journal-title":"Annual Reports in Medicinal Chemistry"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"FSO73","DOI":"10.4155\/fso.15.73","article-title":"The case of galantamine: Repurposing and late blooming of a cholinergic drug","volume":"1","author":"Mucke","year":"2015","journal-title":"Future Sci. Oa"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"183","DOI":"10.2174\/1567205016666190228123923","article-title":"Synthesis of New Galanthamine-Peptide Derivatives Designed for Prevention and Treatment of Alzheimer\u2019s Disease","volume":"16","author":"Vezenkov","year":"2019","journal-title":"Curr. Alzheimer Res."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.phrs.2019.03.014","article-title":"Expanding spectrum of anticancer drug, imatinib, in the disorders affecting brain and spinal cord","volume":"143","author":"Kumar","year":"2019","journal-title":"Pharmacol. Res."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"12444","DOI":"10.1073\/pnas.1534745100","article-title":"Gleevec inhibits beta-amyloid production but not Notch cleavage","volume":"100","author":"Netzer","year":"2003","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"1295","DOI":"10.3233\/JAD-160840","article-title":"Do Cancer Drugs Counteract Neurodegeneration? Repurposing for Alzheimer\u2019s Disease","volume":"55","author":"Monacelli","year":"2017","journal-title":"J. Alzheimer\u2019s Dis. Jad."},{"key":"ref_121","doi-asserted-by":"crossref","unstructured":"He, P., Cheng, X., Staufenbiel, M., Li, R., and Shen, Y. (2013). Long-term treatment of thalidomide ameliorates amyloid-like pathology through inhibition of \u03b2-secretase in a mouse model of Alzheimer\u2019s disease. PLoS ONE, 8.","DOI":"10.1371\/journal.pone.0055091"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.nbd.2007.08.019","article-title":"Thalidomide inhibition of perturbed vasculature and glial-derived tumor necrosis factor-\u03b1 in an animal model of inflamed Alzheimer\u2019s disease brain","volume":"29","author":"Ryu","year":"2008","journal-title":"Neurobiol. Dis."},{"key":"ref_123","doi-asserted-by":"crossref","first-page":"341","DOI":"10.1016\/j.phrs.2010.12.002","article-title":"The characterization of microtubule-stabilizing drugs as possible therapeutic agents for Alzheimer\u2019s disease and related tauopathies","volume":"63","author":"Brunden","year":"2011","journal-title":"Pharm. Res."},{"key":"ref_124","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1073\/pnas.0406361102","article-title":"Microtubule-binding drugs offset tau sequestration by stabilizing microtubules and reversing fast axonal transport deficits in a tauopathy model","volume":"102","author":"Zhang","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"311","DOI":"10.2147\/NDT.S61309","article-title":"The emerging role of bexarotene in the treatment of Alzheimer\u2019s disease: Current evidence","volume":"11","author":"Tousi","year":"2015","journal-title":"Neuropsychiatr. Dis. Treat."},{"key":"ref_126","doi-asserted-by":"crossref","first-page":"1206","DOI":"10.1248\/bpb.b12-00314","article-title":"Tamibarotene: A candidate retinoid drug for Alzheimer\u2019s disease","volume":"35","author":"Fukasawa","year":"2012","journal-title":"Biol. Pharm. Bull."},{"key":"ref_127","doi-asserted-by":"crossref","unstructured":"Hayes, C., Dey, D., Palavicini, J., Wang, H., Patkar, K., Minond, D., Nefzi, A., and Lakshmana, M. (2013). Striking reduction of amyloid plaque burden in an Alzheimer\u2019s mouse model after chronic administration of carmustine. BMC Med., 11.","DOI":"10.1186\/1741-7015-11-81"},{"key":"ref_128","first-page":"17","article-title":"Trimetazidine prevents oxidative changes induced in a rat model of sporadic type of Alzheimer\u2019s disease","volume":"53","author":"Hassanzadeh","year":"2015","journal-title":"Acta Med. Iran."},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000345791","article-title":"A review: Treatment of Alzheimer\u2019s disease discovered in repurposed agents","volume":"35","author":"Appleby","year":"2013","journal-title":"Dement. Geriatr. Cogn. Disord."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2174\/156720506777632835","article-title":"RNA therapeutics directed to the non coding regions of APP mRNA, in vivo anti-amyloid efficacy of paroxetine, erythromycin, and N-acetyl cysteine","volume":"3","author":"Tucker","year":"2006","journal-title":"Curr. Alzheimer Res."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"738","DOI":"10.3389\/fphar.2019.00738","article-title":"Doxycycline for Alzheimer\u2019s Disease: Fighting \u03b2-Amyloid Oligomers and Neuroinflammation","volume":"10","author":"Balducci","year":"2019","journal-title":"Front. Pharm."},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/pcn.12637","article-title":"Therapeutic role of rifampicin in Alzheimer\u2019s disease","volume":"72","author":"Yulug","year":"2018","journal-title":"Psychiatry Clin. Neurosci."},{"key":"ref_133","first-page":"2905","article-title":"Time to test antibacterial therapy in Alzheimer\u2019s disease","volume":"142","author":"Panza","year":"2019","journal-title":"Brain"},{"key":"ref_134","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1111\/j.1755-5949.2010.00231.x","article-title":"Clioquinol: Review of its mechanisms of action and clinical uses in neurodegenerative disorders","volume":"18","author":"Bareggi","year":"2012","journal-title":"CNS Neurosci."},{"key":"ref_135","doi-asserted-by":"crossref","first-page":"1225","DOI":"10.3233\/JAD-180263","article-title":"Metformin Use Associated with Reduced Risk of Dementia in Patients with Diabetes: A Systematic Review and Meta-Analysis","volume":"65","author":"Campbell","year":"2018","journal-title":"J. Alzheimer\u2019s Dis. Jad."},{"key":"ref_136","doi-asserted-by":"crossref","first-page":"784","DOI":"10.1111\/bcp.12997","article-title":"R- and S-citalopram concentrations have differential effects on neuropsychiatric scores in elders with dementia and agitation","volume":"82","author":"Ho","year":"2016","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_137","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1007\/s12035-014-8751-4","article-title":"Valproic acid alleviates memory deficits and attenuates amyloid-\u03b2 deposition in transgenic mouse model of Alzheimer\u2019s disease","volume":"51","author":"Xuan","year":"2015","journal-title":"Mol. Neurobiol."},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.brainresbull.2009.09.003","article-title":"Valproic acid as a promising agent to combat Alzheimer\u2019s disease","volume":"81","author":"Zhang","year":"2010","journal-title":"Brain Res. Bull."},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"2458","DOI":"10.1016\/j.neurobiolaging.2014.05.016","article-title":"Zileuton restores memory impairments and reverses amyloid and tau pathology in aged Alzheimer\u2019s disease mice","volume":"35","author":"Lauretti","year":"2014","journal-title":"Neurobiol. Aging"},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"83","DOI":"10.31887\/DNC.2019.21.1\/bbendlin","article-title":"Antidiabetic therapies and Alzheimer disease","volume":"21","author":"Bendlin","year":"2019","journal-title":"Dialogues Clin. Neurosci."}],"container-title":["Pharmaceuticals"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/9\/242\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T10:09:15Z","timestamp":1760177355000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1424-8247\/13\/9\/242"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9,11]]},"references-count":140,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2020,9]]}},"alternative-id":["ph13090242"],"URL":"https:\/\/doi.org\/10.3390\/ph13090242","relation":{},"ISSN":["1424-8247"],"issn-type":[{"value":"1424-8247","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,9,11]]}}}